Articles by Jordana Jampel
For postoperative morbidity and mortality, surgery alone had the highest probability rate.
The FAK inhibitor narmafotinib targets solid tumors in pancreatic cancer.
mFOLFIRINOX plus CRT did not improve R0 resection nor OS compared with nFOLFIRINOX without CRT.
The primary endpoint was PFS, which was a median of 3.5 months for S-1 and 3.7 months for 5-FU.
FLOT and nivo seems to be associated with improved efficacy, whereas chemo followed by IO therapy is insufficient.
Neoadjuvant nivolumab plus relatlimab led to a pathologic response rate of 96%.
A novel KRAS G12D degrader has an acceptable safety profile and positive antitumor activity, especially in pancreatic cancer.
1L zanidatamab plus chemo with or without bevacizumab demonstrated antitumor activity and manageable safety in mCRC.
The use of EUS and multimodal AI across all levels of endoscopic expertise proved beneficial.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.